P

Peter A. Riedell

University of Chicago

ORCID: 0000-0003-2719-0580

Publishes on CAR-T cell therapy research, Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research. 289 papers and 6.1k citations.

PubIndex Score96Top 4% · mid-careerHow it's scored

289Publications

6.1kTotal Citations

First publication: 2012First senior author: 2012

CAR-T cell therapy research Lymphoma Diagnosis and Treatment Chronic Lymphocytic Leukemia Research Biosimilars and Bioanalytical Methods Viral Infectious Diseases and Gene Expression in Insects

Top publicationsby citations

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nathan Fowler, Catherine Thiéblemont, Andy I. Chen et al.|Nature Medicine|2021

Cited by 523

Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Austin I. Kim, Mark A. Murakami, Philippe Armand et al.|Blood|2023

Cited by 6

Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)

Austin Kim, Mark A. Murakami, Peter A. Riedell et al.|Blood|2025

Cited by 4

289 | MULTICENTER REAL‐WORLD OUTCOMES OF FRONTLINE POLA‐R‐CHP IN TREATMENT NAÏVE DLBCL

Alex F. Herrera, Liangyi Chen, Sophie Buller et al.|Hematological Oncology|2025

Cited by 2

Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)

Austin I. Kim, Mark A. Murakami, Philippe Armand et al.|Blood|2024

Cited by 2